HRP20210108T1 - Liječenje migrene s acetil-leucinom - Google Patents

Liječenje migrene s acetil-leucinom Download PDF

Info

Publication number
HRP20210108T1
HRP20210108T1 HRP20210108TT HRP20210108T HRP20210108T1 HR P20210108 T1 HRP20210108 T1 HR P20210108T1 HR P20210108T T HRP20210108T T HR P20210108TT HR P20210108 T HRP20210108 T HR P20210108T HR P20210108 T1 HRP20210108 T1 HR P20210108T1
Authority
HR
Croatia
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
migraine
Prior art date
Application number
HRP20210108TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Strupp
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210108(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of HRP20210108T1 publication Critical patent/HRP20210108T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20210108TT 2017-06-14 2018-06-25 Liječenje migrene s acetil-leucinom HRP20210108T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine
EP18749124.6A EP3638370B1 (en) 2017-06-14 2018-06-25 Treatment of migraine with acetyl-leucine

Publications (1)

Publication Number Publication Date
HRP20210108T1 true HRP20210108T1 (hr) 2021-03-19

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210108TT HRP20210108T1 (hr) 2017-06-14 2018-06-25 Liječenje migrene s acetil-leucinom

Country Status (25)

Country Link
US (1) US11471434B2 (https=)
EP (1) EP3638370B1 (https=)
JP (1) JP7130739B2 (https=)
KR (1) KR102594130B1 (https=)
CN (1) CN111093772B (https=)
AU (1) AU2018284330B2 (https=)
CY (1) CY1123860T1 (https=)
DK (1) DK3638370T3 (https=)
ES (1) ES2847169T3 (https=)
GB (1) GB201709459D0 (https=)
HR (1) HRP20210108T1 (https=)
HU (1) HUE053089T2 (https=)
IL (1) IL271211B2 (https=)
LT (1) LT3638370T (https=)
MA (1) MA49396B1 (https=)
MD (1) MD3638370T2 (https=)
MX (1) MX387909B (https=)
PL (1) PL3638370T3 (https=)
PT (1) PT3638370T (https=)
RS (1) RS61481B1 (https=)
SG (1) SG11201912146RA (https=)
SI (1) SI3638370T1 (https=)
SM (1) SMT202100037T1 (https=)
WO (1) WO2018229738A1 (https=)
ZA (1) ZA201908087B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337081B2 (ja) * 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
SI1867644T1 (sl) * 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
EP1664041B1 (en) * 2003-09-22 2008-07-02 Euro-Celtique S.A. Phenyl-carboxamide compounds useful for treating pain
PL1664016T3 (pl) * 2003-09-22 2009-04-30 Euro Celtique Sa Środki terapeutyczne przydatne do leczenia bólu
ES2322907T3 (es) * 2003-12-30 2009-07-01 Euro-Celtique S.A. Piperazinas utiles para el tratamiento de dolor.
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2011162409A1 (en) * 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
MX340112B (es) * 2010-11-09 2016-06-27 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
US9394293B2 (en) * 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US10905670B2 (en) 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
FI3600276T3 (fi) 2017-03-28 2023-06-29 Intrabio Ltd Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
LT3697399T (lt) 2017-10-18 2026-01-12 Intrabio Ltd Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
JP7337081B2 (ja) 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
WO2020178721A1 (en) 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
SI3989962T1 (sl) 2019-06-28 2025-11-28 Intrabio Ltd Kombinirano zdravljenje z acetil-levcinom in miglustatom za zdravljenje lizosomske bolezni kopičenja
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
CY1123860T1 (el) 2022-05-27
HUE053089T2 (hu) 2021-06-28
WO2018229738A1 (en) 2018-12-20
GB201709459D0 (en) 2017-07-26
RU2020100475A (ru) 2021-07-14
RS61481B1 (sr) 2021-03-31
CN111093772A (zh) 2020-05-01
JP7130739B2 (ja) 2022-09-05
ZA201908087B (en) 2024-11-27
PL3638370T3 (pl) 2021-05-17
RU2020100475A3 (https=) 2021-10-22
KR20210013518A (ko) 2021-02-04
AU2018284330B2 (en) 2024-03-14
SI3638370T1 (sl) 2021-04-30
CN111093772B (zh) 2023-11-03
ES2847169T3 (es) 2021-08-02
EP3638370A1 (en) 2020-04-22
US11471434B2 (en) 2022-10-18
MA49396A (fr) 2020-04-22
IL271211B1 (en) 2023-09-01
MX2019014784A (es) 2021-11-16
DK3638370T3 (da) 2021-01-25
AU2018284330A1 (en) 2020-01-02
MD3638370T2 (ro) 2021-04-30
IL271211A (en) 2020-01-30
LT3638370T (lt) 2021-03-25
CA3067321A1 (en) 2018-12-20
EP3638370B1 (en) 2020-11-11
PT3638370T (pt) 2021-01-26
JP2020526575A (ja) 2020-08-31
US20200253905A1 (en) 2020-08-13
IL271211B2 (en) 2024-01-01
KR102594130B1 (ko) 2023-10-24
BR112019026660A2 (pt) 2020-07-14
MX387909B (es) 2025-03-19
MA49396B1 (fr) 2021-03-31
SG11201912146RA (en) 2020-01-30
SMT202100037T1 (it) 2021-03-15

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
Citrome Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
WO2015121348A3 (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
RU2015143836A (ru) Лейцин и никотиновая кислота для снижения уровня липидов
MX2009011898A (es) Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
WO2015194764A3 (ko) 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
BR112021018591A2 (pt) Compostos e usos dos mesmos
HRP20201627T1 (hr) Postupak liječenja s tradipitantom
MX2021014029A (es) Formulaciones, fabricación y usos de imatinib.
TN2017000498A1 (en) Positive allosteric modulators of muscarinic m2 receptor
PH12019550263A1 (en) A Pharmaceutical Composition for Anaemia
HRP20210108T1 (hr) Liječenje migrene s acetil-leucinom
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2017106175A3 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
EA202090467A1 (ru) ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
ZA202000028B (en) Use of vibegron to treat overactive bladder
WO2014111790A3 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
BR112018007118A2 (pt) método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
WO2017161402A8 (en) Formulation and method for the prevention and/or treatment of hangover symptoms
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti